Welcome to our dedicated page for NOVN news (Ticker: NOVN), a resource for investors and traders seeking the latest updates and insights on NOVN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NOVN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NOVN's position in the market.
Novan, Inc. (Nasdaq: NOVN) will host its 2020 Annual Meeting of Stockholders (ASM) on July 28, 2020, at 9:30 a.m. ET via a live audio webcast due to the COVID-19 pandemic. Stockholders of record as of June 11, 2020, can vote electronically and ask questions during the meeting. Guests may listen but cannot submit questions. Online check-in starts at 9:15 a.m. ET. Novan is focused on using nitric oxide for treating various diseases, emphasizing its potential benefits in dermatology and women's health.
Novan anticipates its cash position will cover costs for an additional Phase 3 pivotal trial for SB206, targeting molluscum treatment (B-SIMPLE4). The company has secured approximately $16.9 million since June 1, 2020, from stock purchase agreements and warrant exercises. Enrollment for the trial is set for September 2020, with top-line results expected in late Q2 2021, pending no COVID-19 disruptions. Notably, there are currently no FDA-approved therapies for molluscum, highlighting the unmet need SB206 aims to address.
Novan, Inc. (Nasdaq: NOVN) will present a corporate overview at the Life Sciences Investor Forum on June 25, 2020, at 2:00 p.m. Eastern. CEO Paula Brown Stafford will lead the presentation, which will include a real-time Q&A session for investors. Attendees can access the live webcast via the Company's website. An archived version will be available post-event. Novan, a clinical development-stage biotechnology company, focuses on leveraging nitric oxide to treat various diseases, addressing significant unmet medical needs.
Summary not available.